pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
AdCom · news · pharmadog
← back to AdCom
News · AdCom
115
stories
22d
Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug
raps
22d
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
Capricor Duchenne cell therapy voted down by FDA panel
biopharma dive
22d
Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy
endpoints
22d
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
fiercebiotech
22d
NYU's Neil Vasan departs as acting chair of FDA's cancer drug advisory panel
endpoints
22d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
22d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
23d
STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
stat
23d
FDA reminds investors about the risks of advisory panels
endpoints
23d
FDA staff say Replimune's melanoma trial failed to prove RP1 works
endpoints
23d
The future of gray-market peptides
endpoints
23d
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
23d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
24d
Capricor's DMD therapy lacks efficacy, FDA says ahead of adcomm
endpoints
24d
Six wellness peptides win backing from FDA advisory committee
endpoints
24d
UPDATE: FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy
biospace
24d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
24d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
25d
FDA has recommitted to adcomms—but to what end?
biospace
25d
EMA says it takes ultimate responsibility for protecting online meeting registration, survey information
raps
27d
Opinion: I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
stat
27d
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
stat
27d
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
27d
A new, separate outbreak of the diarrhea-causing parasite
stat
28d
FDA panel endorses broader use of certain peptides
biopharma dive
28d
This Week at FDA: Diamantas touts onshoring efforts, grants for DHTs, and more
raps
28d
FDA advisory committee backs two more peptides, rejects one for compounding list
raps
28d
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
stat
← prev
page 2 of 4
next →
